

Development Pipeline Progress Status

Launch Projections - POC Pipeline-

As of July 31, 2026

■ Approved
 ■ Filed and preparing for filing

	FY2025	FY2026	FY2027	FY2028	FY2029 -	
US 		ONO-4059 (VELEXBRU) PCNSL	QINLOCK GIST 2L		ONO-0530 sapablursen PV	ONO-4578 GC 1L ONO-2808 MSA
EU 	ROMVIMZA TGCT		QINLOCK GIST 2L		ONO-0530 sapablursen PV	ONO-4578 GC 1L ONO-2808 MSA
JP 	OPDIVO HCC 1L OPDIVO MSI-H CRC 1L BRAFTOVI CRC 1L FOLFOX	ONO-2017 cenobamate Partial-onset seizures QINLOCK GIST 4L VELEXBRU R/R SCNSL	OPDIVO Unresectable anaplastic Thyroid Cancer 1L OPDIVO HCC Adjuvant ONO-2017 cenobamate Primary generalized tonic-clonic seizures	ripretinib (QINLOCK) GIST 2L VELEXBRU Pemphigus 2L ONO-8531 povetacicept IgAN	ONO-5532 Gel-One Osteoarthritis ONO-2017 cenobamate Partial-onset seizures pediatric vimseltinib (ROMVIMZA) TGCT OPDIVO sc	ONO-0530 sapablursen PV ONO-8531 povetacicept pMN ONO-4578 GC 1L ONO-2808 MSA

PCNSL: Primary Central Nervous System Lymphoma, GIST: Gastrointestinal Stromal Tumor, PV: Polycythemia Vera, GC: Gastric Cancer, MSA: Multiple System Atrophy, TGCT: Tenosynovial Giant Cell Tumor, HCC: Hepatocellular Carcinoma, CRC: Colorectal Cancer, IgAN: IgA Nephropathy, pMN: Primary Membranous Nephropathy

New additions to this earnings call

Development pipeline (Oncology) ①



As of July 31, 2026

Code (Generic name) MOA, Modality	Target Indication	PI	PI/II	PII	PIII	F	A	Status	Area	ID
ONO-4059 (tirabrutinib) BTK inhibitor	PCNSL 1L, ≥2L							2026.2 US : Filed (Part A)	US	NCT04947319
	SCNSL							2026.6 JP : Filed	JP	jRCT2031220529
	PCNSL ≥2L							FY2027 Primary Completion	US	NCT07104032
QINLOCK DCC-2618 (ripretinib) KIT inhibitor	GIST 2L KIT Exon 11+17/18							FY2027 Primary Completion	US, EU, KR, TW and others	NCT05734105
	GIST 4L							FY2027 Primary Completion	JP	NCT07618377
ONO-0530 (sapablursen) Antisense oligonucleotide targeting TMPRSS6	Polycythemia vera (PV)							FY2028 Primary Completion	JP, US, EU, KR, TW and others	NCT07429266
ONO-4578 PG receptor (EP4) antagonist	Gastric cancer*							FY2025 Primary Completion (Actual)	JP, KR, TW	NCT06256328
	Colorectal cancer*							FY2027 Primary Completion	JP, US, EU and others	NCT06948448
	Non-small cell lung cancer*							FY2026 Primary Completion	JP	NCT06542731
ONO-4482 (relatlimab) Anti-LAG-3 antibody	Melanoma*							FY2024 Primary Completion (Actual)	JP, US, EU and others	NCT01968109
ONO-7427 Anti-CCR8 antibody	Solid tumor*							FY2031 Primary Completion	JP, US, EU and others* ¹	NCT04895709
DCC-3116 (inlexisertib) ULK inhibitor	Advanced malignancies (with ripretinib)							FY2026 Primary Completion	US, EU	NCT05957367

PCNSL: Primary central nervous system lymphoma
 SCNSL: Relapsed or refractory secondary central nervous system lymphoma
 GIST: Gastrointestinal Stromal Tumor

MOA : Mode of Action
 * : Combination with OPDIVO

★¹ : Development right country: JP
 Estimated study completion date shown in jRCT or ClinicalTrials.gov

F : Filed, A : Approval
 EU : European countries

※Red: Update after announcement of FY 2025 financial result in May 2026

Development pipeline (Oncology) ②



As of July 31, 2026

Code (Generic name) MOA, Modality	Target Indication	PI	PI/II	PII	PIII	F	A	Status	Area	ID
DCC-3009 Pan-KIT inhibitor	GIST							FY2028 Primary Completion	US	NCT06630234
ONO-4685 (besufetamig) PD-1 x CD3 bispecific antibody	T-cell lymphoma							FY2027 Primary Completion	US	NCT05079282
								FY2028 Primary Completion	JP	NCT06547528
ONO-8250 iPSC-derived HER2 CAR T-cell therapy	HER2-expressing solid tumor							FY2029 Primary Completion	US	NCT06241456
ONO-7428 Anti-ONCOKINE-1 antibody	Solid tumor							FY2029 Primary Completion	JP	NCT06816108
DCC-2812 GCN2 activator	Renal cell carcinoma, urothelial cancer, castration-resistant Prostate cancer							FY2028 Primary Completion	US	NCT06966024
ONO-7429 Anti-L1CAM ADC	Solid tumor							FY2028 Primary Completion	JP	Under registration

GIST: Gastrointestinal Stromal Tumor

* : Combination with OPDIVO

Estimated study completion date shown in jRCT or ClinicalTrials.gov

MOA : Mode of Action

F : Filed, A : Approval

※Red: Update after announcement of FY 2025 financial result in May 2026

Development pipeline (Non-oncology) ①



As of July 31, 2026

Code (Generic name) MOA, Modality	Target Indication	PI	PI/II	P II	P III	F	A	Status	Area	ID
ONO-2017 (cenobamate) Inhibition of voltage-gated sodium currents/positive allosteric modulator of GABA _A ion channel	Partial-onset seizures							FY2025 JP : Filed	JP, KR and others★ ¹	NCT04557085
	Partial-onset seizures (pediatric)							FY2028 Primary Completion	JP	NCT07594158
	Primary generalized tonic-clonic seizures							FY2026 Primary Completion	JP	NCT06579573
VELEXBRU Tablet (ONO-4059: tirabrutinib) BTK inhibitor	Pemphigus							FY2027 Primary Completion	JP	NCT06696716
ONO-8531 (povetacicept) BAFF/APRIL dual antagonist	IgA nephropathy							FY2027 Primary Completion	JP, US, EU, KR, TW and others★ ²	NCT06564142
	Primary membranous nephropathy				★ ³			FY2028 Primary Completion	US, EU, KR and others★ ²	NCT07204275
ONO-5532 (Gel-One) Cross-linked hyaluronate	Knee osteoarthritis							FY2027 Completion	JP	jRCT2031240621
	Hip osteoarthritis							FY2027 Completion	JP	jRCT2061240110
ROMVIMZA DCC-3014 (vimseltinib) CSF-1R inhibitor	Tenosynovial giant cell tumor (TGCT)							—	JP	Under registration
	Chronic graft versus host disease (cGVHD)							FY2029 Primary Completion	US	NCT06619561
ONO-2808 S1P5 receptor agonist	Multiple system atrophy (MSA)							FY2025 Primary Completion (Actual)	JP, US	NCT05923866

Development pipeline (Non-oncology) ②



As of July 31, 2026

Code (Generic name) MOA, Modality	Target Indication	PI	PI/II	PII	PIII	F	A	Status	Area	ID
ONO-1110 Endocannabinoid regulation	Postherpetic neuralgia							FY2026 Primary Completion	JP	NCT06708416
	Fibromyalgia							FY2026 Primary Completion	JP	NCT06752590
	Hunner type interstitial cystitis							FY2026 Primary Completion	JP	NCT06752603
	Major depressive disorder							FY2026 Primary Completion	JP	NCT06792136
	Social anxiety disorder							FY2026 Primary Completion	JP	NCT06805565
ONO-2020 Epigenetic Regulation	Alzheimer's disease							FY2026 Primary Completion	JP, US	NCT06881836
	Agitation associated with dementia due to Alzheimer's disease							FY2026 Primary Completion	JP	NCT06803823
ONO-4685 (besufetamig) PD-1 x CD3 bispecific antibody	Autoimmune disease							FY2024 Completion	JP	jRCT2071220081
								FY2024 Primary Completion (Actual)	EU	NCT05332704
ONO-4915 PD-1 x CD19 bispecific antibody	Autoimmune disease							FY2026 Completion	JP	jRCT2071240056
ONO-2416	Psychiatric disease							FY2027 Completion	JP	jRCT2071250147
ONO-3310	Kidney disease							FY2027 Completion	JP	jRCT2071260026
ONO-6414	Autoimmune disease							FY2027 Primary Completion	US	Under registration
ONO-3401	Neurological disease							FY2027 Completion	JP	jRCT2071260067

MOA : Mode of Action

Estimated study completion date shown in jRCT or ClinicalTrials.gov
Shaded boxes indicate studies on healthy volunteers.

F : Filed, A : Approval
EU : European countries

※Red: Update after announcement of FY 2025 financial result in May 2026